OR WAIT null SECS
Click here to read the articles and download the PDF
How the development of more quantitative and qualitative data around the patient can drive better-informed care decisions—and help avoid potential overstock scenarios that can deplete earnings
State and regional economic-development authorities compete fiercely for siting new pharma enterprises, and holding onto the ones they have. But pharma’s stupendous growth in investment is giving all regions a boost
How pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization
Gains in temperature-controlled logistics, accelerated by the pandemic, have reshaped the landscape for global pharma distribution—making it crucial to maintain investment levels in four key areas
September 17, 2021
Both Comirnaty, Spikevax jabs had previously been authorized for use under Interim Order
September 16, 2021
Deal is dependent on FDA approval of Phathom’s vonoprazan compound
Availability of space for new labs is a key selling point
September 15, 2021
Acquisition expected to help provide customers with a quicker clinical trial recruitment process
Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot
September 14, 2021
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
September 13, 2021
Latest construction plan continues CDMO’s vision for biopharma expansion
FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance
September 10, 2021
Biotech firm to file regulatory dossier with officials around the world
September 09, 2021
CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand
.jpg?w=900&fit=crop&auto=format)
.jpeg?w=900&fit=crop&auto=format)